##  [Understanding the Revised CTIS Transparency Rules for Clinical Trials](/e-books/understanding-the-revised-ctis-transparency-rules-for-clinical-trials) 

- [Medicinal Products](/e-books-category/medicinal-products)
- [Regulatory Affairs](/e-books-category/regulatory-affairs)





 ![Understanding the Revised CTIS Transparency Rules for Clinical Trials]()

The European Medicines Agency (EMA) had revised its transparency rules for the Clinical Trials Information System (CTIS) and was effective from October 2023. These changes aim to simplify processes, enhance transparency, and protect sensitive information, benefiting patients and clinical researchers across the EU. Initially launched in January 2022 under the Clinical Trials Regulation (EU) No 536/2014, CTIS faced challenges due to the complexity of its deferral mechanism. Feedback from stakeholders highlighted the need for clearer publication rules and improved user experience. The revised rules focus on publishing structured data fields and key documents earlier, simplifying the deferral mechanism, and maintaining high levels of data protection. The implementation of these changes is expected to improve user experience, enhance public access to clinical trial information, and reduce administrative burdens for sponsors.



Fill the form below to download the e-Book

 You must have JavaScript enabled to use this form.

  

  

  

 How did you hear about us?Search EngineE-mail CampaignGoogle AdsSocial MediaLink from another websiteColleague’s RecommendationNewsletterPrinted BrochureOther 

  

 

 

     I have read the [privacy policy](https://www.freyrsolutions.com/privacy-policy) 



 

 Submitted Page URL  

 Website URL  

 Content Type  

 Form Name